- cafead   Jun 10, 2024 at 11:40: AM
via Moderna on Monday unveiled Phase III data for its investigational combination vaccine mRNA-1083, which demonstrated a superior immune response against COVID-19 and influenza compared to licensed vaccines.
article source
article source